TFG Asset Management GP Ltd Invests $1.32 Million in Dyne Therapeutics, Inc. $DYN

by · The Cerbat Gem

TFG Asset Management GP Ltd acquired a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN – Free Report) during the 2nd quarter, Holdings Channel reports. The fund acquired 138,375 shares of the company’s stock, valued at approximately $1,317,000. Dyne Therapeutics accounts for about 0.2% of TFG Asset Management GP Ltd’s investment portfolio, making the stock its 28th largest holding.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. CWM LLC raised its holdings in Dyne Therapeutics by 168.1% in the second quarter. CWM LLC now owns 3,030 shares of the company’s stock worth $29,000 after buying an additional 1,900 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its position in shares of Dyne Therapeutics by 378.6% during the first quarter. Caitong International Asset Management Co. Ltd now owns 3,092 shares of the company’s stock valued at $32,000 after acquiring an additional 2,446 shares in the last quarter. Quarry LP bought a new stake in shares of Dyne Therapeutics during the first quarter valued at approximately $47,000. Ameritas Investment Partners Inc. raised its holdings in Dyne Therapeutics by 11.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 9,582 shares of the company’s stock worth $91,000 after acquiring an additional 955 shares during the last quarter. Finally, Prudential Financial Inc. bought a new position in Dyne Therapeutics in the 2nd quarter valued at approximately $111,000. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Trading Down 1.4%

Shares of NASDAQ:DYN opened at $19.42 on Friday. The stock’s 50-day simple moving average is $19.05 and its two-hundred day simple moving average is $14.22. The stock has a market capitalization of $2.77 billion, a price-to-earnings ratio of -5.31 and a beta of 1.30. Dyne Therapeutics, Inc. has a 52-week low of $6.36 and a 52-week high of $27.59. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.47 and a current ratio of 13.47.

Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.05. Analysts expect that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Analyst Ratings Changes

A number of research firms have commented on DYN. Sanford C. Bernstein set a $23.00 target price on Dyne Therapeutics in a report on Tuesday. Tudor Pickering set a $23.00 price objective on Dyne Therapeutics in a research report on Tuesday. Oppenheimer raised Dyne Therapeutics from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $11.00 to $40.00 in a research report on Wednesday. JPMorgan Chase & Co. dropped their price target on shares of Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating on the stock in a report on Friday, November 14th. Finally, Lifesci Capital upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 14th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $38.59.

Get Our Latest Report on Dyne Therapeutics

About Dyne Therapeutics

(Free Report)

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

Recommended Stories

Want to see what other hedge funds are holding DYN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dyne Therapeutics, Inc. (NASDAQ:DYN – Free Report).